Art

J-GLOBAL ID：201902275621676799   Reference number：19A1104518

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

表皮成長因子受容体チロシンキナーゼ阻害剤に対する抵抗性の機構と潜在的治療戦略【JST・京大機械翻訳】

Author (3)： Nagano Tatsuya (Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan) ,  Tachihara Motoko (Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan) ,  Nishimura Yoshihiro (Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan)
Material： Cells (Web)
Volume： 7  Issue： 11  Page： 212  Publication year： 2018 
JST Material Number： U7155A  ISSN： 2073-4409  Document type： Article
Article type： 文献レビュー  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Treatment with epidermal growt...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1104518&from=J-GLOBAL&jstjournalNo=U7155A") }}

Thesaurus term： Proteins ,  Recurrence ,  *EGF receptor ,  human ,  small cell lung cancer ,  non-small cell lung cancer ,  HGF ,  effectiveness ,  *therapeutic planning ,  Mutation ,  BCL-2 ,  overexpression ,  Epithelial-Mesenchymal Transition ,  *tyrosine kinase inhibitor ,  Genetic Variation ,  enzyme inhibitor
Semi thesaurus term： variation(biology) , 【Automatic Indexing@JST】

Author keywords (6)： acquired resistance ,  T790M ,  C797S ,  alternative pathway ,  transformation ,  primary resistance

JST classification (2)： Infectious diseases,parasitics diseases in general.  (GD01010H) ,  Congenital diseases,deformities in general.  (GD03010V)

Substance index (1)： Erlotinib

Reference (120)：

• Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
• Paez, J.G.; Jänne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
• Kobayashi, Y.; Togashi, Y.; Yatabe, Y.; Mizuuchi, H.; Jangchul, P.; Kondo, C.; Shimoji, M.; Sato, K.; Suda, K.; Tomizawa, K.; et al. EGFR exon 18 mutations in lung cancer: Molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs. Clin. Cancer Res. 2015, 21, 5305-5313.
• Kobayashi, S.; Boggon, T.J.; Dayaram, T.; Jänne, P.A.; Kocher, O.; Meyerson, M.; Johnson, B.E.; Eck, M.J.; Tenen, D.G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352, 786-792.
• Pao, W.; Miller, V.A.; Politi, K.A.; Riely, G.J.; Somwar, R.; Zakowski, M.F.; Kris, M.G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2, e73.

Terms in the title (4)： 表皮成長因子受容体 ,  チロシンキナーゼ阻害剤 ,  抵抗性 ,  治療戦略